Mander steps up to take Domainex reins
Domainex Ltd has appointed Dr Tom Mander as its new CEO. He takes the reins when Dr Trevor Perrior retires from the role in April.
Mander has almost 30 years of experience in small-molecule drug discovery and joined Domainex as chief operating officer in March 2015 with a mandate to achieve organic expansion of the drug discovery service business of the company.
Perrior said: “I am very pleased that Tom has agreed to take over as chief executive. He joined the company with the remit of growing our business with global biotech and pharma companies and during the past five years of working together we have greatly expanded our strong service offering and built Domainex into a leading international CRO.
“I am confident that under Tom’s leadership Domainex will continue to grow and remain at the forefront of drug discovery technology providers.”
Mander added: “It’s a privilege to work with all of our stakeholders and I am grateful to the board for this opportunity to build on the company’s achievements.
“With over 40 clients and approximately 50 per cent of our business coming from overseas, the last five years have marked our emergence as a global player in the drug discovery marketplace.
“With the exceptionally talented and dedicated team of scientists that we have assembled, I am confident that Domainex will continue to be an industry leader in the discovery of new medicines for our clients.”
Mander started his career at Amersham International, then became a senior scientist at Xenova before being appointed as a group leader managing high-throughput screening at Glaxo Wellcome.
He has been involved in contract drug discovery for the past 21 years, holding operational, business development, and marketing roles at Evotec AG before taking executive management positions at Tripos Discovery Research (Vice President of Business Development) and Asterand (Vice President of Sales and Marketing) prior to their respective trade sales.
Before joining Domainex, he was director of business development in the Early Discovery division of Charles River, formerly BioFocus.